https://ift.tt/2IVHF6y

Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension.

from Markets https://ift.tt/2MwjmsS

Comments

Popular posts from this blog

MPL accuses ASCI of 'tampering' with ads